Crowdonomics
All companies

Algernon Neuroscience Inc.

Operating

Biotech · Vancouver

Estimated pre-money ⓘ
$10.0M
As of Jan 2025 · from Reg A Offering (2025) · our estimate: offering price × shares outstanding, not a stated valuation
Total raised
$0
Across 2 rounds since 2022
Latest share price
$0.50
Reg A Offering (2025) offering price

Financials

FY2021–FY2024 (no data for FY2022) · from SEC filings · hover any figure for its source
$0
−$1.2M
2021
2022no data
$0
−$752K
2023
$0
−$752K
2024
RevenueNet income — beside revenue when positive, below the line when a loss
Metric
FY2021 audited
FY2023 audited
FY2024 audited
Income statement
Revenue
$0
$0
$0
Cost of goods sold
$1,231,089
$749,254
$749,254
Net income
-$1,232,974
-$751,782
-$751,782
Balance sheet
Cash
$0
$1
$1
Accounts receivable
$0
$0
$0
Total assets
$34,755
$39,964
$39,964
Long-term debt
$0
$0
$0
Total liabilities
$1,937,016
$1,655,031
$1,655,031
Other
Headcount
0
0
0

Figures as reported by the issuer in the filing shown on hover. Each year’s pill shows the assurance level of its filed statements — audited, reviewed (CPA review, less than an audit), or unaudited, as the filing’s own report or certification states it. A dashed pill marked * is inferred instead: the SEC minimum for an offering that size, which the issuer may have exceeded. No pill means we couldn’t tell. Headcount is the filing’s point-in-time count, not a year-end average. Manually corrected figures are marked “Corrected”.

Valuation over rounds

Pre-money — the valuation set before each round’s money came in
$20.0M
est. pre-money
$10.0M
est. pre-money
Reg A+ · Equity · Dec 2022
Reg A+ · Equity · Jan 2025

Dotted grey bars are our estimate for rounds that didn't state one: the round's share price × the shares outstanding in its filings. Same measure as blue, but rougher.

Cap table

Share counts as of Apr 2, 2025
ClassOutstandingVotes / shareShare of totalLast price
Common20,000,001—100.0%—

From the company's SEC filings: share counts per class, each class's voting and conversion terms, and the holders of 20% or more that Form C requires (officers and 10%+ holders on Form 1-A). Filings name only large holders, so most owners — including crowd investors — are not listed, and a holder's percentage may be of its own class rather than of the whole company. Prices and crowd share counts are in today's share terms — adjusted for splits and conversions since they were sold. Hover a figure for its filing.

Fundraising history

Reg A+ · Equity · Jan 2025Withdrawnvia Netcapital
Raised $0 / $5MEst. pre-money $10M
Reg A+ · Equity · Dec 2022Closedvia DALMORE GROUP LLC
Raised $0 / $10MEst. pre-money $20M

Team

7 people
Christopher J. Moreau
Chief Executive Officer and Director
Christopher Bryan
Vice President of Research and Operations
James Kinley
Chief Financial Officer and Secretary
Harry J.F. Bloomfield KC
Chairman of the Board of Directors
Howard Gutman
Director
Mark Williams
Director
Raj Attariwala
Director

Names and titles as disclosed on SEC Form 1-A. Bios and photos come from the platform campaign page and may be out of date.

  • Form 1-A-WApr 13, 20260001062993-26-001956
    EDGAR
  • Form 1-A/AApr 2, 20250001062993-25-006674
    EDGAR
  • Form 1-A/AMar 6, 20250001062993-25-004716
    EDGAR
  • Form 1-AJan 24, 20250001062993-25-001035
    EDGAR
  • Form 1-A-WDec 11, 20230001062993-23-022286
    EDGAR
  • Form 1-ZDec 11, 20230001062993-23-022287
    EDGAR
  • Form 253G2Apr 6, 20230001062993-23-008826
    EDGAR
  • Form QUALIFMar 8, 20239999999994-23-000101
    EDGAR
Source: SEC EDGARCIK 0001959708British Columbia, CanadaShare price $0.50Last synced Aug 16, 2026

About this data. Figures are compiled from public sources — SEC EDGAR filings (Form C, C-AR, 1-A, 1-K) and funding-platform pages — and may be delayed, incomplete, or restated by the issuer. Financial statements are as reported by the issuer; each year is labeled with its assurance level (audited / reviewed / unaudited). A valuation cap is the conversion ceiling of a SAFE or convertible note, not an agreed company valuation; post-money figures are computed as pre-money plus amount raised and are not a traded price. Crowdonomics is not a broker-dealer, funding portal, or investment adviser; nothing here is investment advice or an offer to sell securities. Verify all figures against the linked EDGAR filings.